Pacific Biosciences is trading 10.64% higher at $1.56, with no clear company-specific catalyst identified for September 24, 2026. - The biotechnology sector is declining, while broader markets are mixed, so the gain does not clearly align with sector or macro direction. - PacBio’s latest listed announcement was its September 3 Morgan Stanley healthcare conference participation; September 24 company events are industry conferences, not material financial announcements. - The move may reflect trading activity or speculative demand.